Headquartered in Joshua Dawson House, Dublin Fiscal year ends December NASDAQ: GHRS ghres.com
GH Research PLC is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies for depression, with an initial focus on treatment-resistant depression (TRD).
Its lead candidate is GH001, an inhalable mebufotenin formulation. GH001 is being transitioned from a third-party vaporizer to the company's proprietary GH001 Aerosol Delivery System (ADS), which supports a single fixed dose per treatment visit. GH002 is an intravenous mebufotenin candidate.
Clinical progress to date:
- GH001 met its primary endpoint in a Phase 2b TRD trial.
- It showed remission in all patients in a Phase 2a postpartum depression trial.
- It has also been studied in bipolar II disorder.
The company plans a global TRD pivotal program after an FDA End-of-Phase 2 meeting expected in Q1 2027, and a postpartum depression pivotal program targeted for the second half of 2027.
GH Research has generated no revenue. It funds operations through equity offerings, including an April 2026 offering, and maintains a $200 million at-the-market program. The company reports a single R&D segment. Updated
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks…
GH Research PLC is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies for depression, with an initial focus on treatment-resistant depression (TRD). Its lead candidate is GH001, an inhalable mebufotenin formulation.
The Wall Street consensus 12-month price target for GHRS is $42.89.
